SAGE Therapeutics Inc (SAGE.OQ)

Mon, Jan 7 2019

Sage shares soar after oral postpartum depression treatment succeeds in trial

Sage Therapeutics Inc said on Monday its oral treatment for postpartum depression met the main goal of reducing symptoms of the condition, when compared to a placebo in a late-stage study, sending its shares up 33 percent.

UPDATE 1-Sage shares soar after oral postpartum depression treatment succeeds in trial

Jan 7 Sage Therapeutics Inc said on Monday its oral treatment for postpartum depression met the main goal of reducing symptoms of the condition, when compared to a placebo in a late-stage study, sending its shares up 33 percent.

Sage's oral postpartum depression treatment succeeds in late-stage study

Jan 7 Sage Therapeutics Inc said on Monday its oral treatment for postpartum depression met the main goal of reducing symptoms of the condition, when compared to a placebo in a late-stage study.

FDA panel recommends Sage's postpartum depression treatment

An advisory panel to the U.S. Food and Drug Administration on Friday recommended Sage Therapeutics Inc's experimental treatment for postpartum depression, saying the benefits of the drug outweighed risks.

UPDATE 2-FDA panel recommends Sage's postpartum depression treatment

Nov 2 An advisory panel to the U.S. Food and Drug Administration on Friday recommended Sage Therapeutics Inc's experimental treatment for postpartum depression, saying the benefits of the drug outweighed risks.

Sage's postpartum depression treatment benefits outweigh risk: FDA panel

Nov 2 The benefits of Sage Therapeutics Inc's experimental treatment for postpartum depression outweigh risks, an advisory panel to the U.S. Food and Drug Administration said on Friday.

Select another date: